The FDA ordered that the class of drugs known as TNF blockers carry a warning on the packaging that their use carries the risk of developing a potentially deadly fungal disease called histoplasmosis. [...]
|
|||||||
 |
Psoriatic arthritis is a joint disease developed by and estimated 20 to 40 percent of psoriasis patients. Detecting the disease in the early stages can provide an opportunity to administer treatments that can lessen the damage to the joints. Pharmaceutical company PharmaGenoma, through its subsidiary PsoriasisDx, has developed a genetic test to assist doctors in [...] Etanercept, marketed under the name Enbrel, is a drug that belongs to the class of drugs known as tumor necrosis factor (TNF)-alpha blocker. It is used primarily to treat rheumatoid arthritis, but has also been approved for use in treating polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis. On May 1st, the U.S. [...] Today marks the 4th observance of World Psoriasis Day. The purpose is to increase awareness of this genetic immune system disease which affects 7.5 million people in the U.S. and 125 million people around the world. Psoriasis is a non-contagious skin condition that can lead to other serious conditions, including heart disease, diabetes, liver disease [...] I have posted in the past about the links discovered between various forms of arthritis and genetics. Here are a couple more genes that have been identified with an increased risk in arthritis. HLA-B27 The first gene, HLA-B27, was determined in the 1960’s to have a link with spondyloarthropathies, which are a group of diseases that affect [...] |
  
|
|||||
|
Copyright © 2010 Current Arthritis News and Research - All Rights Reserved
|
|||||||
Recent Comments